Antitumor Effects of Imidazoquinolines in Urothelial Cell Carcinoma of the Bladder

Journal of Urology

Volumn 177, Issue 6, 2007, Pages 2347-2351

  Smith, Eric B ^a   Schwartz, Michael ^a   Kawamoto, Hideki ^a   You, Xueke ^a   Hwang, David ^a   Liu, Huixian ^a   Scherr, Douglas S ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

bladder; carcinoma; immunotherapy; mice; transitional cell

Indexed keywords

CYTOKINE; IMIDAZOQUINOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER TUMOR; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; UROTHELIAL CELL CARCINOMA;

AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; MICE; TOLL-LIKE RECEPTOR 7; URINARY BLADDER NEOPLASMS;

EID: 34248204151     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.01.112     Document Type: Article

References (20)

1. Morales A., Eidinger D., and Bruce A.W. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116 (1976) 180
2. Lamm D.L. Intravesical therapy for superficial bladder cancer: slow but steady progress. J Clin Oncol 21 (2003) 4259
3. Seya T., Akazawa T., Uehori J., Matsumoto M., Azuma I., and Toyoshima K. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res 23 (2003) 4369
4. Cook D.N., Pisetcky D.S., and Schwartz D.A. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 5 (2004) 975
5. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 (2004) 987
6. Kodner C.M., and Nasraty S. Management of genital warts. Am Fam Physician 70 (2004) 2335
7. Tyring S., Conant M., Marini M., Van Der Meijden W., and Washenik K. Imiquimod; an international update on therapeutic uses in dermatology. Int J Dermatol 41 (2002) 810
8. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3 (2002) 196
9. Kikuchi E., Xu S., Ohori M., Matei C., Lupu M., Menendez S., et al. Detection and quantitative analysis of early stage orthotopic murine bladder tumor using in vivo magnetic resonance imaging. J Urol 170 (2003) 1375
10. Krejci K.G., Markiewicz M.A., and Kwon E.D. Immunotherapy for urological malignancies. J Urol 171 (2004) 870
11. Patard J.J., Rodriguez A., and Lobel B. The current status of intravesical therapy for superficial bladder cancer. Curr Opin Urol 13 (2003) 357
12. Geisse J., Caro I., Lindholm J., Golitz L., Stampone P., and Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 505 (2004) 722
13. Witt P.L., Ritch P.S., Reding D., McAuliffe T.L., Westrick L., Grossberg S.E., et al. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res 53 (1993) 5176
14. Schon M., Bong A.B., Drewniok C., Herz J., Geilen C.C., Reifenberger J., et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 95 (2003) 1138
15. Meyer T., Nindl I., Schmook T., Ulrich C., Sterry W., and Stockfleth E. Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br J Dermatol 149 suppl. (2003) 9
16. Schon M.P., Wienrich B.G., Drewniok C., Bong A.B., Gollnick H., Schon M., et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 122 (2004) 1266
17. Albert M.L., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86
18. Smith E.B., Albert M.L., You X., Masse D., and Scherr D.S. Antigen cross presentation and cross priming in the treatment of superficial bladder cancer: the role of bCG invoked specific CD8+ T cell response against bladder tumor antigens. J Urol 171 suppl. (2004) abstract 712
19. Schon M.P., and Schon M. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 9 (2004) 291
20. Imbertson L.M., Beaurline J.M., Couture A.M., Gibson S.J., Smith R.M., Miller R.L., et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 110 (1998) 734